

Notice of References Cited	Application/Control No. 17/025,881	Applicant(s)/Patent Under Reexamination Chodavarapu et al.	
	Examiner CARLOS A AZPURU	Art Unit 1617	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-20170143719-A1	05-2017	Parker; Michael G.	A61K31/515	1/1
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office
PTO-892 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 20220315



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

149344 7590 03/30/2022
Umberg Zipser LLP
1920 Main Street Suite 750
Irvine, CA 92614

EXAMINER

AZPURI, CARLOS A.

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 03/30/2022

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/025,881	09/18/2020	Bala Tripura Sundari Chodavarapu	104078.0001US	8113

TITLE OF INVENTION: Lyophilized Compositions of Phenobarbital Sodium Salt

APPL. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$600	\$0.00	\$0.00	\$600	06/30/2022

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

149344 7590 03/30/2022
Umberg Zipser LLP
1920 Main Street Suite 750
Irvine, CA 92614

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/025,881	09/18/2020	Bala Tripura Sundari Chodavarapu	104078.0001US	8113

TITLE OF INVENTION: Lyophilized Compositions of Phenobarbital Sodium Salt

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$600	\$0.00	\$0.00	\$600	06/30/2022

EXAMINER	ART UNIT	CLASS-SUBCLASS
AZPURU, CARLOS A	1617	424-489000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/AIA/122 or PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/AIA/47 or PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☐ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☐ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. Change in Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/025,881	09/18/2020	Bala Tripura Sundari Chodavarapu	104078.0001US	8113
149344	7590	03/30/2022	EXAMINER	
Umberg Zipser LLP 1920 Main Street Suite 750 Irvine, CA 92614			AZPURI, CARLOS A	
			ART UNIT	PAPER NUMBER
			1617	

DATE MAILED: 03/30/2022

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.** Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b) (2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt	
EFS ID:	46090842
Application Number:	17025881
International Application Number:	
Confirmation Number:	8113
Title of Invention:	Lyophilized Compositions of Phenobarbital Sodium Salt
First Named Inventor/Applicant Name:	Bala Tripura Sundari Chodavarapu
Customer Number:	149344
Filer:	Martin Fessenmaier/Danielle Moroz
Filer Authorized By:	Martin Fessenmaier
Attorney Docket Number:	104078.0001US
Receipt Date:	30-JUN-2022
Filing Date:	18-SEP-2020
Time Stamp:	14:55:32
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$600
RAM confirmation Number	E20226TE56064701
Deposit Account	601823
Authorized User	Danielle Moroz
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: 37 CFR 1.16 (National application filing, search, and examination fees) 37 CFR 1.17 (Patent application and reexamination processing fees)	

37 CFR 1.19 (Document supply fees)
 37 CFR 1.20 (Post Issuance fees)
 37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	Issue_Fee_Payment.pdf	138525	no	1
			e790a6887ac9d7276545dcd63703032ad10a74ef		

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	37646	no	2
			7c6da551848c5efad621072c73587499fa98a9e		

Warnings:

Information:

Total Files Size (in bytes):	176171
-------------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

149344 7590 03/30/2022
Umberg Zipser LLP
1920 Main Street Suite 750
Irvine, CA 92614

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

Danielle Moroz	(Typed or printed name)
/Danielle Moroz/	(Signature)
June 30, 2022	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/025,881	09/18/2020	Bala Tripura Sundari Chodavarapu	104078.0001US	8113

TITLE OF INVENTION: Lyophilized Compositions of Phenobarbital Sodium Salt

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	\$600	\$0.00	\$0.00	\$600	06/30/2022

EXAMINER	ART UNIT	CLASS-SUBCLASS
AZPURU, CARLOS A	1617	424-489000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/AIA/122 or PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/AIA/47 or PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Umberg Zipser LLP

2

3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

NIVAGEN PHARMACEUTICALS, INC.

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Sacramento, CA

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government4a. Fees submitted: ☒ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☒ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. 601823

5. Change in Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29☐ Applicant asserting small entity status. See 37 CFR 1.27☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature: /Martin Fessenmaier/

Date: June 30, 2022

Typed or printed name: Martin Fessenmaier

Registration No. 46697

Electronic Patent Application Fee Transmittal				
Application Number:		17025881		
Filing Date:		18-Sep-2020		
Title of Invention:		Lyophilized Compositions of Phenobarbital Sodium Salt		
First Named Inventor/Applicant Name:		Bala Tripura Sundari Chodavarapu		
Filer:		Martin Fessenmaier/Danielle Moroz		
Attorney Docket Number:		104078.0001US		
Filed as Small Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	2501	1	600	600

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				600



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/025,881	08/09/2022	11406598	104078.0001US	8113
149344	7590	07/20/2022		
Umberg Zipser LLP 1920 Main Street Suite 750 Irvine, CA 92614				

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Patents Stakeholder Experience (OPSE), Stakeholder Support Division (SSD) at (571)-272-4200.

INVENTOR(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional inventors):

Bala Tripura Sundari Chodavarapu, Davis, CA;
Thirupathi Mangali, Sacramento, CA;
Jay Shukla, Sacramento, CA;
Anand Shukla, Denver, CO;
Dasaradhi Lakkaraju, Sacramento, CA;

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Nivagen Pharmaceuticals, Inc., Sacramento, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

IR103 (Rev. 10/09)

To: rdean@umbergzipser.com,patents@umbergzipser.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 149344

Jul 21, 2022 04:25:38 AM

Dear PAIR Customer:

Umberg Zipser LLP
1920 Main Street Suite 750
Irvine, CA 92614
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 149344 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
17025881	ISSUE.NTF	07/20/2022	104078.0001US

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

507409868 07/28/2022

PATENT ASSIGNMENT COVER SHEETElectronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7456796

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
NIVAGEN PHARMACEUTICALS, INC.	07/28/2022
RECEIVING PARTY DATA	
Name:	CORBEL CAPITAL PARTNERS SBIC, L.P.
Street Address:	11777 SAN VICENTE BLVD., SUITE 777
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90049
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	17499001
Application Number:	17466063
Application Number:	17707237
Application Number:	17025881
Application Number:	17871058
CORRESPONDENCE DATA	
Fax Number:	(949)725-4100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9497254043
Email:	amina@stradlinglaw.com
Correspondent Name:	ARNOLD V MINA
Address Line 1:	STRADLING YOCCA CARLSON & RAUTH
Address Line 2:	660 NEWPORT CENTER DRIVE, SUITE 1600
Address Line 4:	NEWPORT BEACH, CALIFORNIA 92660
ATTORNEY DOCKET NUMBER:	103864-0022
NAME OF SUBMITTER:	ARNOLD V. MINA
SIGNATURE:	/Arnold V. Mina/
DATE SIGNED:	07/28/2022
This document serves as an Oath/Declaration (37 CFR 1.63).	

Total Attachments: 5

source=Corbel.Nivagen- Patent Security Agreement#page1.tif

source=Corbel.Nivagen- Patent Security Agreement#page2.tif

source=Corbel.Nivagen- Patent Security Agreement#page3.tif

source=Corbel.Nivagen- Patent Security Agreement#page4.tif

source=Corbel.Nivagen- Patent Security Agreement#page5.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this “**Patent Security Agreement**”) is made this 28th day of July, 2022, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “**Grantors**” and each individually “**Grantor**”), and CORBEL CAPITAL PARTNERS SBIC, L.P., as administrative agent (“**Agent**”) for the benefit of the Purchasers (as defined below).

W I T N E S S E T H

WHEREAS, pursuant to that certain Secured Promissory Note and Warrant Purchase Agreement dated as of July 28, 2022 (as amended, restated, supplemented, or otherwise modified from time to time, the “**Note Purchase Agreement**”) by and among Nivagen Pharmaceuticals, Inc., a Delaware corporation (“**Nivagen**”), and one or more additional direct or indirect Subsidiaries of Nivagen hereafter acquired or formed, which become party to the Note Purchase Agreement by executing an Addendum (Nivagen and such other Subsidiaries are sometimes individually referred to herein as an “**Issuer**” and collectively referred to herein as “**Issuers**” or “**Issuer**”), the Purchasers of the Notes named therein (the “**Purchasers**”) and Agent, Agent and the Purchasers agreed to make certain financial accommodations available to Issuers from time to time pursuant to the terms and conditions thereof; and

WHEREAS, Agent and the Purchasers are willing to make the financial accommodations to Issuers as provided for in the Note Purchase Agreement, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Purchasers, that certain Security Agreement, dated as of even date with the Note Purchase Agreement (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “**Security Agreement**”); and

WHEREAS, pursuant to the Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Purchasers, this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. **DEFINED TERMS**. All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement or, if not defined therein, in the Note Purchase Agreement.

2. **GRANT OF SECURITY INTEREST IN PATENT COLLATERAL**. Each Grantor hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of the Purchasers, to secure the Secured Obligations, a continuing security interest (referred to in this Patent Security Agreement as the “**Security Interest**”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “**Patent Collateral**”):

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I;

Patent Security Agreement

(b) all divisionals, continuations, continuations-in-part, reissues, reexaminations, or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future infringement of any Patent or any Patent exclusively licensed under any Intellectual Property License, including the right to receive damages, or right to receive license fees, royalties, and other compensation under any Patent Intellectual Property License.

3. SECURITY FOR SECURED OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. SECURITY AGREEMENT. The Security Interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interests granted to Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Patent Security Agreement and the Security Agreement, the Security Agreement shall control.

5. AUTHORIZATION TO SUPPLEMENT. If any Grantor shall obtain rights to any new patent application or issued patent or become entitled to the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent application, the provisions of this Patent Security Agreement shall automatically apply thereto. Grantors shall give notice in writing to Agent with respect to any such new patent rights in accordance with the terms of the Security Agreement. Without limiting Grantors' obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Patent Security Agreement by amending Schedule I to include any such new patent rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

6. COUNTERPARTS. This Patent Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Patent Security Agreement. Delivery of an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Patent Security Agreement. Any party delivering an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Patent Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Patent Security Agreement.

[signature page follows]

Patent Security Agreement

IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first above written.

GRANTOR:

NIVAGEN PHARMACEUTICALS, INC.

By: 

Name: Jay Shukla

Title: President and Chief Executive Officer


[Signature Page to Patent Security Agreement]

AGENT:

ACCEPTED AND ACKNOWLEDGED BY:

CORBEL CAPITAL PARTNERS SBIC, L.P.

By: Corbel Capital Advisors SBIC, LLC,
its General Partner

By: 
Name: Jeffrey B. Schwartz
Title: Managing Member

By: 
Name: Jeffrey S. Scrota
Title: Managing Member

By: 
Name: Michael H. Jones
Title: Managing Member

[Signature Page to Patent Security Agreement]

SCHEDULE I
to
PATENT SECURITY AGREEMENT

Patents

Title of Invention	Filing/Patent No.	Filing/Issue Date	Owner of Record
Ready-To-Use Potassium Phosphates In Sodium Chloride Solutions	17/499,001	Filed October 12, 2021	Nivagen Pharmaceuticals, Inc.
Pantoprazole Compositions and Methods	17/446,063	Filed August 26, 2021	Nivagen Pharmaceuticals, Inc.
Chlorthalidone Compositions And Methods	17/707,237	Filed May 26, 2021	Nivagen Pharmaceuticals, Inc.
Lyophilized Compositions of Phenobarbital Sodium Salt	17/025,881	Filed September 18, 2020	Nivagen Pharmaceuticals, Inc.
Calcium Gluconate Formulation Without Calcium Saccharate	17/871,058	Filed July 2022	Nivagen Pharmaceuticals, Inc.

Patent Security Agreement

508541368 05/10/2024

PATENT ASSIGNMENT COVER SHEETElectronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI224254

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the patent application no. 17/466,063 as the application number was entered incorrectly due to a typographic error. Such typographic error was made in good faith. The correct patent application number appearing on the recorded document is 17/446,063, previously recorded on Reel 60657 Frame 158. Assignor(s) hereby confirms the Security Interest.
CONVEYING PARTY DATA	
Name	Execution Date
NIVAGEN PHARMACEUTICALS, INC.	07/28/2022
RECEIVING PARTY DATA	
Company Name:	CORBEL CAPITAL PARTNERS SBIC, L.P.
Street Address:	11777 San Vicente Blvd., Suite 777
City:	Los Angeles
State/Country:	CALIFORNIA
Postal Code:	90049
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	17499001
Application Number:	17707237
Application Number:	17025881
Application Number:	17871058
Application Number:	17446063
CORRESPONDENCE DATA	
Fax Number:	9497254100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9497254043
Email:	amina@stradlinglaw.com
Correspondent Name:	Mr. Arnold V Mina
Address Line 1:	660 Newport Center Drive, Suite 1600
Address Line 4:	Newport Beach, CALIFORNIA 92660
ATTORNEY DOCKET NUMBER:	103864-0022
NAME OF SUBMITTER:	ARNOLD MINA
SIGNATURE:	ARNOLD MINA

DATE SIGNED:	05/10/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).
Total Attachments: 7 source=NIVAGEN ASSIGNMENT RECORDATION#page1.tif source=NIVAGEN ASSIGNMENT RECORDATION#page2.tif source=NIVAGEN ASSIGNMENT RECORDATION#page3.tif source=NIVAGEN ASSIGNMENT RECORDATION#page4.tif source=NIVAGEN ASSIGNMENT RECORDATION#page5.tif source=NIVAGEN ASSIGNMENT RECORDATION#page6.tif source=NIVAGEN ASSIGNMENT RECORDATION#page7.tif	

507409868 07/28/2022

PATENT ASSIGNMENT COVER SHEETElectronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7456796

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
NIVAGEN PHARMACEUTICALS, INC.	07/28/2022
RECEIVING PARTY DATA	
Name:	CORBEL CAPITAL PARTNERS SBIC, L.P.
Street Address:	11777 SAN VICENTE BLVD., SUITE 777
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90049
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	17499001
Application Number:	17466063
Application Number:	17707237
Application Number:	17025881
Application Number:	17871058
CORRESPONDENCE DATA	
Fax Number:	(949)725-4100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9497254043
Email:	amina@stradlinglaw.com
Correspondent Name:	ARNOLD V MINA
Address Line 1:	STRADLING YOCCA CARLSON & RAUTH
Address Line 2:	660 NEWPORT CENTER DRIVE, SUITE 1600
Address Line 4:	NEWPORT BEACH, CALIFORNIA 92660
ATTORNEY DOCKET NUMBER:	103864-0022
NAME OF SUBMITTER:	ARNOLD V. MINA
SIGNATURE:	/Arnold V. Mina/
DATE SIGNED:	07/28/2022
This document serves as an Oath/Declaration (37 CFR 1.63).	

507409868

PATENT
REEL: 060657 FRAME: 0158

Total Attachments: 5

source=Corbel.Nivagen- Patent Security Agreement#page1.tif

source=Corbel.Nivagen- Patent Security Agreement#page2.tif

source=Corbel.Nivagen- Patent Security Agreement#page3.tif

source=Corbel.Nivagen- Patent Security Agreement#page4.tif

source=Corbel.Nivagen- Patent Security Agreement#page5.tif

PATENT

REEL: 060657 FRAME: 0159

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this “**Patent Security Agreement**”) is made this 28th day of July, 2022, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “**Grantors**” and each individually “**Grantor**”), and CORBEL CAPITAL PARTNERS SBIC, L.P., as administrative agent (“**Agent**”) for the benefit of the Purchasers (as defined below).

WITNESSETH:

WHEREAS, pursuant to that certain Secured Promissory Note and Warrant Purchase Agreement dated as of July 28, 2022 (as amended, restated, supplemented, or otherwise modified from time to time, the “**Note Purchase Agreement**”) by and among Nivagen Pharmaceuticals, Inc., a Delaware corporation (“**Nivagen**”), and one or more additional direct or indirect Subsidiaries of Nivagen hereafter acquired or formed, which become party to the Note Purchase Agreement by executing an Addendum (Nivagen and such other Subsidiaries are sometimes individually referred to herein as an “**Issuer**” and collectively referred to herein as “**Issuers**” or “**Issuer**”), the Purchasers of the Notes named therein (the “**Purchasers**”) and Agent, Agent and the Purchasers agreed to make certain financial accommodations available to Issuers from time to time pursuant to the terms and conditions thereof; and

WHEREAS, Agent and the Purchasers are willing to make the financial accommodations to Issuers as provided for in the Note Purchase Agreement, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Purchasers, that certain Security Agreement, dated as of even date with the Note Purchase Agreement (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “**Security Agreement**”); and

WHEREAS, pursuant to the Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Purchasers, this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. **DEFINED TERMS.** All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement or, if not defined therein, in the Note Purchase Agreement.

2. **GRANT OF SECURITY INTEREST IN PATENT COLLATERAL.** Each Grantor hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of the Purchasers, to secure the Secured Obligations, a continuing security interest (referred to in this Patent Security Agreement as the “**Security Interest**”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “**Patent Collateral**”):

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I;

Patent Security Agreement

1

PATENT
REEL: 060657 FRAME: 0160

(b) all divisionals, continuations, continuations-in-part, reissues, reexaminations, or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future infringement of any Patent or any Patent exclusively licensed under any Intellectual Property License, including the right to receive damages, or right to receive license fees, royalties, and other compensation under any Patent Intellectual Property License.

3. SECURITY FOR SECURED OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. SECURITY AGREEMENT. The Security Interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interests granted to Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Patent Security Agreement and the Security Agreement, the Security Agreement shall control.

5. AUTHORIZATION TO SUPPLEMENT. If any Grantor shall obtain rights to any new patent application or issued patent or become entitled to the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent application, the provisions of this Patent Security Agreement shall automatically apply thereto. Grantors shall give notice in writing to Agent with respect to any such new patent rights in accordance with the terms of the Security Agreement. Without limiting Grantors' obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Patent Security Agreement by amending Schedule I to include any such new patent rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

6. COUNTERPARTS. This Patent Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Patent Security Agreement. Delivery of an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Patent Security Agreement. Any party delivering an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Patent Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Patent Security Agreement.

[signature page follows]

Patent Security Agreement

2

PATENT
REEL: 060657 FRAME: 0161

IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first above written.

GRANTOR:

NIVAGEN PHARMACEUTICALS, INC.

By: 

Name: Jay Shukla

Title: President and Chief Executive Officer

[Signature Page to Patent Security Agreement]


PATENT
REEL: 060657 FRAME: 0162

AGENT:

ACCEPTED AND ACKNOWLEDGED BY:

CORBEL CAPITAL PARTNERS SBIC, L.P.

By: Corbel Capital Advisors SBIC, LLC,
its General Partner

By: 
Name: Jeffrey B. Schwartz
Title: Managing Member

By: 
Name: Jeffrey S. Scrota
Title: Managing Member

By: 
Name: Michael H. Jones
Title: Managing Member

[Signature Page to Patent Security Agreement]

PATENT
REEL: 060657 FRAME: 0163

SCHEDULE I
to
PATENT SECURITY AGREEMENT

Patents


Title of Invention	Filing/Patent No.	Filing/Issue Date	Owner of Record
Ready-To-Use Potassium Phosphates In Sodium Chloride Solutions	17/499,001	Filed October 12, 2021	Nivagen Pharmaceuticals, Inc.
Pantoprazole Compositions and Methods	17/446,063	Filed August 26, 2021	Nivagen Pharmaceuticals, Inc.
Chlorthalidone Compositions And Methods	17/707,237	Filed May 26, 2021	Nivagen Pharmaceuticals, Inc.
Lyophilized Compositions of Phenobarbital Sodium Salt	17/025,881	Filed September 18, 2020	Nivagen Pharmaceuticals, Inc.
Calcium Gluconate Formulation Without Calcium Saccharate	17/871,058	Filed July 2022	Nivagen Pharmaceuticals, Inc.

Patent Security Agreement

4

RECORDED: 07/28/2022

PATENT
REEL: 060657 FRAME: 0164



PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						Application or Docket Number 17/025,881	
APPLICATION AS FILED - PART I							
(Column 1)		(Column 2)		SMALL ENTITY		OTHER THAN SMALL ENTITY	
FOR	NUMBER FILED	NUMBER EXTRA	RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	75		N/A	
SEARCH FEE (37 CFR 1.16(A), (I), or (m))	N/A	N/A	N/A	330		N/A	
EXAMINATION FEE (37 CFR 1.16(e), (p), or (q))	N/A	N/A	N/A	380		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	20	minus 20 = *	x 50 =	0.00			
INDEPENDENT CLAIMS (37 CFR 1.16(h))	2	minus 3 = *	x 230 =	0.00			
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			0.00			
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				0.00			
				TOTAL		TOTAL	
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL		TOTAL	
APPLICATION AS AMENDED - PART II							
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY	
AMENDMENT A	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		OTHER THAN SMALL ENTITY
	Total (37 CFR 1.16(i))	Minus **	=	x =		RATE(\$)	ADDITIONAL FEE(\$)
	Independent (37 CFR 1.16(h))	Minus ***	=	x =		x =	
	Application Size Fee (37 CFR 1.16(s))						
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
				TOTAL ADD'L FEE		TOTAL ADD'L FEE	
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY	
AMENDMENT B	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		OTHER THAN SMALL ENTITY
	Total (37 CFR 1.16(i))	Minus **	=	x =		x =	
	Independent (37 CFR 1.16(h))	Minus ***	=	x =		x =	
	Application Size Fee (37 CFR 1.16(s))						
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
				TOTAL ADD'L FEE		TOTAL ADD'L FEE	
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.							

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875		Application or Docket Number 17/025,881	Filing Date 09/18/2020	☐ To be Mailed	
ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO					
APPLICATION AS FILED - PART I					
FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE (\$)	FEE (\$)	
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A		
☐ SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A		
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A		
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 = *		x \$50 =		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 = *		x \$230 =		
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL		
APPLICATION AS AMENDED - PART II					
AMENDMENT	(Column 1)	(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)
	02/12/2021 CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	* 23 Minus ** 20 = 3		x \$50 =	150
	Independent (37 CFR 1.16(h))	* 2 Minus *** 3 = 0		x \$240 =	0
	☐ Application Size Fee (37 CFR 1.16(s))				
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
				TOTAL ADD'L FEE	150
AMENDMENT	(Column 1)	(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	* Minus ** =		x \$0 =	
	Independent (37 CFR 1.16(h))	* Minus *** =		x \$0 =	
	☐ Application Size Fee (37 CFR 1.16(s))				
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
				TOTAL ADD'L FEE	
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.				LIE	
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".				/LINDA HUMES/	
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".					
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.					

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875		Application or Docket Number 17/025,881	Filing Date 09/18/2020	☒ To be Mailed
---	--	--	---------------------------	--

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE (\$)	FEE (\$)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(b), (j), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 = *		x \$50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 = *		x \$230 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s)) If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED - PART II

	(Column 1)		(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)
AMENDMENT	03/09/2022		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	* 20	Minus	** 23	= 0	x \$50 = 0
	Independent (37 CFR 1.16(h))	* 2	Minus	*** 3	= 0	x \$240 = 0
	☐ Application Size Fee (37 CFR 1.16(s))					
AMENDMENT	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
	TOTAL ADD'L FEE					0
AMENDMENT			HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	*	Minus	**	=	x \$0 =
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x \$0 =
	☐ Application Size Fee (37 CFR 1.16(s))					
AMENDMENT	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
	TOTAL ADD'L FEE					

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
 The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
 /ANGELA D JOHNSON/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office/ U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875		Application or Docket Number 17/025,881	Filing Date 09/18/2020	☐ To be Mailed		
ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO						
APPLICATION AS FILED - PART I						
FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE (\$)	FEE (\$)		
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			
☐ SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A			
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			
TOTAL CLAIMS (37 CFR 1.16(j))	minus 20 = *		x \$50 =			
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 = *		x \$230 =			
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).					
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))						
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			
APPLICATION AS AMENDED - PART II						
AMENDMENT	(Column 1)	(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)	
	12/22/2021	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	* 20	Minus ** 23	= 0	x \$50 =	0
	Independent (37 CFR 1.16(h))	* 2	Minus *** 3	= 0	x \$240 =	0
	☐ Application Size Fee (37 CFR 1.16(s))					
AMENDMENT	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
	TOTAL ADD'L FEE				0	
	(Column 1)	(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)	
	Total (37 CFR 1.16(i))	*	Minus **	=	x \$0 =	
	Independent (37 CFR 1.16(h))	*	Minus ***	=	x \$0 =	
AMENDMENT	☐ Application Size Fee (37 CFR 1.16(s))					
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
	TOTAL ADD'L FEE					
	* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.				LIE	
	** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".				/DAMALI AYANA BERRY/	
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".						
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.						

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/06 (09-11)
 Approved for use through 1/31/2014. OMB 0651-0032
 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875		Application or Docket Number 17/025,881	Filing Date 09/18/2020	☐ To be Mailed
---	--	--	---------------------------	---------------------------------------

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE (\$)	FEE (\$)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(j))	minus 20 = *		x \$50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 = *		x \$230 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED - PART II

	(Column 1)		(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)
AMENDMENT	08/24/2021		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	* 23	Minus	** 23	= 0	x \$50 = 0
	Independent (37 CFR 1.16(h))	* 2	Minus	*** 3	= 0	x \$240 = 0
	☐ Application Size Fee (37 CFR 1.16(s))					
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
					TOTAL ADD'L FEE	0
AMENDMENT			HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	*	Minus	**	=	x \$0 =
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x \$0 =
	☐ Application Size Fee (37 CFR 1.16(s))					
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
					TOTAL ADD'L FEE	
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.					LIE	
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".					/CAROLYN E THOMAS/	
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".						
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.						

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875		Application or Docket Number 17/025,881	Filing Date 09/18/2020	☒ To be Mailed	
ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO					
APPLICATION AS FILED - PART I					
FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE (\$)	FEE (\$)	
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A		
☐ SEARCH FEE (37 CFR 1.16(b), (j), or (m))	N/A	N/A	N/A		
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A		
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 = *		x \$50 =		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 = *		x \$230 =		
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL		
APPLICATION AS AMENDED - PART II					
AMENDMENT	(Column 1)	(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)
	05/13/2021 CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	* 23 Minus ** 23	= 0	x \$50 =	0
	Independent (37 CFR 1.16(h))	* 3 Minus *** 3	= 0	x \$240 =	0
	☐ Application Size Fee (37 CFR 1.16(s))				
AMENDMENT	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))				
	TOTAL ADD'L FEE			0	
	(Column 1)	(Column 2)	(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		
	Total (37 CFR 1.16(i))	* Minus **	=	x \$0 =	
AMENDMENT	Independent (37 CFR 1.16(h))	* Minus ***	=	x \$0 =	
	☐ Application Size Fee (37 CFR 1.16(s))				
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))				
	TOTAL ADD'L FEE				
	* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.			LIE	
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".			/ANGELA D JOHNSON/		
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".					
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.					

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Derwent Innovation Patent Export, 2025-02-13 01:00:59 +0000

Search results for: PNS=(US11406598);

Collections searched: DWPI; ARIPO grant; Argentina UM; Argentina app; Armenia grant; Australia UM; Australia app; Australia grant; Austria UM; Austria app; Austria grant; Belarus UM; Belarus grant; Belgium app; Belgium grant; Brazil UM; Brazil app; Brazil grant; Bulgaria UM; Bulgaria app; Bulgaria grant; Canada app; Canada grant; China, Mainland UM; China, Mainland app; China, Mainland grant; Colombia app; Costa Rica UM; Costa Rica app; Croatia UM; Croatia app; Croatia grant; Cuba app; Cuba grant; Czech Republic UM; Czech Republic app; Czech Republic grant; Czechoslovakia grant; Denmark UM; Denmark app; Denmark grant; Estonia UM; Estonia app; Estonia grant; Eurasian (EAPO) grant; Europe (EP) app; Europe (EP) grant; Finland app; Finland grant; France app; France grant; Georgia grant; German Democratic Republic app; German Democratic Republic grant; Germany UM; Germany app; Germany grant; Greece app; Greece grant; Gulf Cooperation Council grant; Hong Kong UM; Hong Kong app; Hong Kong grant; Hungary grant; Iceland grant; India app; India grant; Indonesia UM; Indonesia app; Ireland UM; Ireland app; Ireland grant; Israel grant; Italy grant; Italy grant; Italy grant; Italy grant; Japan UM; Japan app; Japan grant; Korea UM; Korea app; Korea grant; Latvia grant; Lithuania grant; Luxembourg app; Luxembourg grant; Malaysia app; Malaysia grant; Mexico app; Mexico grant; Moldova UM; Moldova grant; Monaco grant; Mongolia UM; Mongolia grant; Morocco app; Morocco grant; Netherlands app; Netherlands grant; New Zealand grant; Norway app; Norway grant; OAPI grant; PCT (WO) app; Philippines UM; Philippines app; Philippines grant; Poland UM; Poland grant; Portugal UM; Portugal app; Portugal grant; Romania UM; Romania app; Romania granted; Russia UM; Russia app; Russia grant; Saudi Arabia app; Saudi Arabia grant; Serbia UM; Serbia app; Serbia grant; Singapore app; Singapore grant; Slovakia UM; Slovakia app; Slovakia grant; Slovenia UM; Slovenia grant; South Africa app; Spain UM; Spain app; Spain grant; Sweden app; Sweden grant; Switzerland app; Switzerland grant; Taiwan UM; Taiwan app; Taiwan grant; Thailand UM; Thailand app; Thailand grant; Tunisia app; Turkey UM; Turkey app; UK app; UK grant; USSR grant; Ukraine UM; Ukraine grant; United States app; United States grant; Uruguay app; Vietnam UM; Vietnam app; Vietnam grant; Other

Table of Contents

1. US11406598B2 Lyophilized compositions of phenobarbital sodium salt

Family 1/1**1 record(s) per family****Record 1/1** US11406598B2 Lyophilized compositions of phenobarbital sodium salt**Title:** Lyophilized compositions of phenobarbital sodium salt**Title - DWPI:** Pharmaceutical composition for treating individual suffering from epilepsy, comprises lyophilized amorphous phenobarbital sodium**Priority Number:** US62903511P**Priority Date:** 2019-09-20**Application Number:** US17025881A**Application Date:** 2020-09-18**Publication Date:** 2022-08-09**IPC Class Table:**

IPC	Section	Class	Subclass	Class Group	Subgroup
A61K000919	A	A61	A61K	A61K0009	A61K000919
A61K000900	A	A61	A61K	A61K0009	A61K000900
A61K0031515	A	A61	A61K	A61K0031	A61K0031515

IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
A61K0031515	A	A61	A61K	A61K0031	A61K0031515
A61K000900	A	A61	A61K	A61K0009	A61K000900
A61K000919	A	A61	A61K	A61K0009	A61K000919

Assignee/Applicant: NIVAGEN PHARMACEUTICALS INC.,Sacramento,CA,US**JP F Terms:****JP FI Codes:****Assignee - Original:** NIVAGEN PHARMACEUTICALS INC.**Any CPC Table:**

Type	CPC - Current -	CPC - Current -	Version	Office
------	-----------------	-----------------	---------	--------

	Invention	Additional		
Current	A61K 9/19	-	20130101	EP; US
Current	A61K 9/0019		20130101	EP; US
Current	A61K 31/515		20130101	EP; US
Current	A61P 1/00	-	20180101	EP
Original	A61K 9/19	-	20130101	US
Original	A61K 9/0019		20130101	US
Original	A61K 31/515		20130101	US

ECLA:

Abstract:

A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.

Language of Publication: EN

INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact
2024-05-10	AS	-
Description: ASSIGNMENT CORBEL CAPITAL PARTNERS SBIC, L.P., CALIFORNIA CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE PATENT APPLICATION NO. 17/466,063 PREVIOUSLY RECORDED AT REEL: 60657 FRAME: 158. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST; ASSIGNOR:NIVAGEN PHARMACEUTICALS, INC.; REEL/FRAME:067531/0287 2022-07-28		
2022-07-28	AS	-
Description: ASSIGNMENT CORBEL CAPITAL PARTNERS SBIC, L.P., CALIFORNIA SECURITY INTEREST; ASSIGNOR:NIVAGEN PHARMACEUTICALS, INC.; REEL/FRAME:060657/0158 2022-07-28		
2022-07-20	STCF	-
Description: INFORMATION ON STATUS: PATENT GRANT PATENTED CASE		
2022-03-28	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS		

2022-03-10	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER		
2022-02-04	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL NON FINAL ACTION MAILED		
2022-01-07	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL DOCKETED NEW CASE - READY FOR EXAMINATION		
2021-09-21	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL FINAL REJECTION MAILED		
2021-08-26	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER		
2021-05-27	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL NON FINAL ACTION MAILED		
2021-05-14	STPP	-
Description: INFORMATION ON STATUS: PATENT APPLICATION AND GRANTING PROCEDURE IN GENERAL DOCKETED NEW CASE - READY FOR EXAMINATION		
2020-09-28	FEPP	-
Description: FEE PAYMENT PROCEDURE ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY		
2020-09-18	FEPP	-
Description: FEE PAYMENT PROCEDURE ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY		
2020-09-18	AS	-
Description: ASSIGNMENT NIVAGEN PHARMACEUTICALS, INC., CALIFORNIA ASSIGNMENT OF ASSIGNORS INTEREST; ASSIGNORS:CHODAVARAPU, BALA TRIPURA SUNDARI; MANGALI, THIRUPATHI; SHUKLA, JAY; AND OTHERS; REEL/FRAME:053822/0598 2019-09-20		



Post-Issuance (US):

Reassignment (US) Table:

Assignee	Assignor	Date Signed	Reel/Frame	Date
CORBEL CAPITAL PARTNERS SBIC L.P.,LOS ANGELES,CA,US	NIVAGEN PHARMACEUTICALS, INC.	2022-07-28	067531/0287	2024-05-10
Conveyance: CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE PATENT APPLICATION NO. 17/466,063 PREVIOUSLY RECORDED AT REEL: 60657 FRAME: 158. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST.				
Corresponent: MR. ARNOLD V MINA 660 NEWPORT CENTER DRIVE, SUITE 1600 NEWPORT BEACH, CA 92660				
CORBEL CAPITAL PARTNERS SBIC L.P.,LOS ANGELES,CA,US	NIVAGEN PHARMACEUTICALS, INC.	2022-07-28	060657/0158	2022-07-28
Conveyance: SECURITY INTEREST (SEE DOCUMENT FOR DETAILS).				
Corresponent: ARNOLD V MINA STRADLING YOCCA CARLSON & RAUTH 660 NEWPORT CENTER DRIVE, SUITE 1600 NEWPORT BEACH, CA 92660				

Maintenance Status (US):


Litigation (US): 2024-01-23 2024 Nivagen Inc. Sun Pharma Advanced Research Company Ltd. Sun Pharmaceutical Industries Ltd. Sun Pharmaceutical Medicare Ltd. Sun Pharmaceuticals Industries Inc. Texas Eastern District Court 2:24-cv-00036

Opposition (EP):

License (EP):

EPO Procedural Status:

Front Page Drawing:



Priority Number - DWPI: US2019903511P | US17025881A
Priority Date - DWPI: 2019-09-20 | 2020-09-18
Assignee - Current US: NIVAGEN PHARMACEUTICALS INC.

Copyright 2007-2025 CLARIVATE



United States Patent and Trademark Office

Office of the Commissioner for Patents

Lyophilized Compositions of Phenobarbital Sodium Salt

PATENT # 11406598 APPLICATION # 17025881 FILING DATE 09/18/2020 ISSUE DATE 08/09/2022

Payment Window Status

WINDOW	STATUS	FEES	No maintenance fees are due at this time. 3.5 year window opens on 08/09/2025.		
3.5 Year	Not Open	Not Due			
Window	First Day to Pay	Surcharge Starts	Last Day to Pay	Status	Fees
3.5 Year	08/09/2025	02/10/2026	08/10/2026	Not Open	Not Due
7.5 Year	08/09/2029	02/12/2030	08/09/2030	Not Open	Not Due
11.5 Year	08/09/2033	02/10/2034	08/09/2034	Not Open	Not Due

Patent Holder Information

Customer # 149344
Entity Status SMALL
Phone Number 9496790052
Address Umberg Zipser LLP
1920 Main Street Suite 750
Irvine, CA 92614
UNITED STATES